Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 1 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Curadel Surgical Innovations Inc. operates in the Biotechnology & Pharmaceuticals technology area. The company has 4 pending office actions. These actions are distributed among 4 distinct examiners, meaning each pending matter is being reviewed by a different person.
All prosecution activity is concentrated within 1 distinct art unit. WESTERBERG, NISSA M is the busiest examiner, overseeing 1 busiest examiner pending action. This indicates that the 4 pending office actions are divided among the 4 distinct examiners.
The fact that the workload is contained within 1 distinct art unit suggests a high degree of technical similarity in the company's current Biotechnology & Pharmaceuticals filings. However, the involvement of 4 distinct examiners means the company must navigate four different examiner perspectives within that 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTERBERG, NISSA M | 1 | 23.4% | +37.1% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| SCHLIENTZ, LEAH H | 1 | 41.9% | +38.5% |
| PERREIRA, MELISSA JEAN | 1 | 52.0% | +25.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719519 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS FOR IMAGING OF SENTINEL LYMPH NODES | WESTERBERG, NISSA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719519 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS FOR IMAGING OF SENTINEL LYMPH NODES | WESTERBERG, NISSA M | — |
| 18732982 | ZWITTERIONIC METAL CHELATORS | DONOHUE, SEAN R | — |
| 18641149 | DISEASE-TARGETED IMAGING AGENTS | SCHLIENTZ, LEAH H | — |
| 18641097 | TARGETING LIGANDS FOR DISEASE-TARGETED IMAGING AGENTS AND METHODS OF USE THEREFOR | PERREIRA, MELISSA JEAN | — |
| Art Unit | Apps |
|---|---|
| 1618 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18719519 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS FOR IMAGING OF SENTINEL LYMPH NODES | WESTERBERG, NISSA M | — | §103§112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18732982 | ZWITTERIONIC METAL CHELATORS | DONOHUE, SEAN R | 1618 | §103DP | Non-Final OA | — | Pending | Jun 04, 2024 |
| 18641149 | DISEASE-TARGETED IMAGING AGENTS | SCHLIENTZ, LEAH H | 1618 | §103Other | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18641097 | TARGETING LIGANDS FOR DISEASE-TARGETED IMAGING AGENTS AND METHODS OF USE THEREFOR | PERREIRA, MELISSA JEAN | 1618 | §103§112DP | Non-Final OA | — | Pending | Apr 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial